Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/5019608_CN19608_0